Intranasal deferoxamine treatment in a rat model of Parkinsons disease: preliminary results [poster] Conference Poster uri icon
  • Deferoxamine (DFO) has been shown to drastically decrease the behavioral and brain changes of Parkinson's disease (PD) in rat models. However, the benefit was realized when DFO was injected directly into the brain, which is not a possible delivery method for humans. We propose to determine whether DFO delivered intranasally can be used as a treatment for PD in rodent models. PD was induced in rats by injecting 6-hydroxy-dopamine (6-OHDA; which kills dopaminergic neurons) into the medial forebrain bundle (MFB), while sham surgery rats received saline injections. Rats were pre-treated three times with either IN DFO or saline, and post-treated for up to 1 month before behavioral tests were performed. Thus far, we have only completed tests for 5 rats in each treatment group which provides preliminary, but not completely analyzed data. The data show that the model was created successfully, and the trends seen thus far indicate that IN DFO is beneficial in this model. In the drug-induced rotational test, which measures the extent of neuronal damage to the MFB, DFO treatment decreased the number of turns compared to saline treated rats. Also, in the tapered balance beam test, DFO treatment decreased the number of footslips compared to saline treated rats. In both tests, rats given 6-OHDA fared much worse than rats with sham surgery. These results are preliminary and include a small sample size, but if the trends continue with more rats than statistical significance may be obtained, and with it, a potential new treatment for PD.

  • publication date
  • 2012
  • Research
  • Animal Studies
  • Drugs and Drug Therapy
  • Intranasal Administration
  • Parkinson Disease